Favorable clinical outcomes of checkpoint inhibitor-based combinations after progression with immunotherapy in advanced non-small cell lung cancer

Aim: Immune checkpoint inhibitors (ICIs) have dramatically changed the treatment paradigm in patients with non-small-cell lung cancer (NSCLC). However, progression patterns with immunotherapy are currently unclear and therapeutic options beyond resistance remain challenging. Methods: We reviewed adv...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Xin, Chu, Xiangling, Wu, Yan, Zhou, Juan, Zhao, Jing, Zhou, Fei, Han, Chaonan, Su, Chunxia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: OAE Publishing Inc. 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9086517/
https://www.ncbi.nlm.nih.gov/pubmed/35582303
http://dx.doi.org/10.20517/cdr.2021.28

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9086517/
https://www.ncbi.nlm.nih.gov/pubmed/35582303
http://dx.doi.org/10.20517/cdr.2021.28

Ejemplares similares